A Botanical Compound for the Treatment of Alopecia Areata and Chemotherapy-Induced Alopecia.
| Autor: | Patsner B; Legacy Healthcare, Lausanne, Switzerland. Electronic address: b.patsner@legacyhealthcare.ch., Harti S; Legacy Healthcare, Lausanne, Switzerland. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | The journal of investigative dermatology. Symposium proceedings [J Investig Dermatol Symp Proc] 2020 Nov; Vol. 20 (1), pp. S69-S70. |
| DOI: | 10.1016/j.jisp.2020.04.009 |
| Abstrakt: | Legacy Healthcare has developed and patented a topical botanical with a unique mechanism of action, an extensive clinical data package, and excellent safety from the 2.2 million units already sold, all of which has enabled it to enter late-stage clinical development for alopecia areata (AA), chemotherapy-induced alopecia, and soon female androgenetic alopecia. As this drug candidate is very safe, the European Medicines Agency agreed to Legacy Healthcare's request to initiate late-stage clinical trial first in children, the neediest population suffering from AA. The initial trend from the phase II/III trial conducted to assess the efficacy and safety of the drug candidate in pediatric AA (RAAINBOW trial) looks promising, although no conclusions can be made. This drug candidate seems to offer several potential safety and economic advantages over other investigational synthetic and biologic compounds currently being investigated in populations with AA overall and especially for children. (Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|